Skip to main content
main-content

Type 2 diabetes medications

medwireNews feature

Fournier gangrene: A challenge for risk–benefit communication

Doctor patient consultation

The recent postmarketing data on Fournier gangrene in people taking sodium-glucose cotransporter 2 inhibitors has increased concerns about this very rare but potentially fatal side effect. medwireNews talks to primary care diabetes specialist Kevin Fernando about how the findings affect risk–benefit considerations.

medwireNews top story

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

Kidneys

Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.

The REWIND trial

Cardiovascular disease (illustration)
ADA 2019

The DUAL VIII trial

Insulin pens
ADA 2019

The PIONEER trials

diabetes_pills_syringe
Expert opinion editorial

The CAROLINA trial: Make or break for sulfonylureas?

Sulfonylurea pill

Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas. 

Get more on: Sulfonylureas | DPP-4 inhibitors | Other diabetes medications

medwireNews top story

Postmarketing data support Fournier gangrene link with SGLT2 inhibitors

Critical care

Fournier gangrene remains very rare, but is more common in people using SGLT2 inhibitors compared with other diabetes medications and has severe consequences, shows research.

medwireNews top story

Ellipse trial: Liraglutide expands treatment options for pediatric type 2 diabetes

Injection pens

The Ellipse investigators report improved glycemic control at the price of early and mostly mild gastrointestinal events in children and adolescents with type 2 diabetes.

medwireNews top story

Canagliflozin may offer renal protection in people with type 2 diabetes and CKD

Pills in hand

Findings from the CREDENCE trial indicate that the SGLT2 inhibitor canagliflozin reduces the risk for renal failure and cardiovascular disease among individuals with type 2 diabetes and albuminuric chronic kidney disease.

Webinar

The continuing evolution of GLP-1RAs

The continuing evolution of GLP-1RAs

Join John Wilding, Kamlesh Khunti, and Julie Lovshin on Wednesday 8 May at 19:00-20:00 (BST) for a live webinar discussion with an expert faculty on the continuing evolution of glucagon-like peptide-1 receptor agonists (GLP-1RAs). Find out more and register here.

medwireNews

07-16-2019 | Insulin | News

Early hypoglycemia common after starting basal insulin therapy

Almost one in 10 people with type 2 diabetes who begin basal insulin therapy through the Medicare health program experience hypoglycemia within 6 months, US research suggests.

07-15-2019 | Medications | News

Second-line type 2 diabetes therapies vary globally

Second-line therapy choices for people with type 2 diabetes vary widely throughout the world and are influenced not only by clinical characteristics but also non-medical factors such as affordability and availability, results from the DISCOVER study show.

07-11-2019 | Insulin glargine | News

Support for Gla-300 use in older people with type 2 diabetes

Older type 2 diabetes patients receiving basal insulin treatment who switch to glargine 300 units/mL experience greater or similar improvements in glycemic control compared with those switching to a first-generation basal insulin, with lower hypoglycemia risk, researchers report.

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

12-13-2018 | GLP-1 agonists | Review | Article

GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Sposito AC et al. Cardiovasc Diabetol 2018; 17: 157. doi: 10.1186/s12933-018-0800-2

11-27-2018 | Insulin | Article

Insulin injection technique questionnaire: Results of an international study comparing Brazil, Latin America and World data

Calliari LE et al. Diabetol Metab Syndr 2018; 10: 85. doi: 10.1186/s13098-018-0389-3

11-15-2018 | Pregnancy | Article

Successful outcomes with insulin degludec in pregnancy: A case series

Hiranput S et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0532-z

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

Image Credits